3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
8
Sarcopenia
2
Prostatic Neoplasms
2
Obesity
2
Melanoma
2
Malnutrition
2
Colorectal Neoplasms
2
Breast Carcinoma In Situ
2
Wound Infection
1
Weight Loss
1
Surgical Wound Infection
1
Skin Neoplasms
1
Psoriasis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Postoperative Complications
1
Polycystic Ovary Syndrome
1
Phagocyte Bactericidal Dysfunction
1
Pain
1
Paget's Disease, Mammary
1
Osteoarthritis
1
Olfaction Disorders
1
Neoplasms
1
Neoplasm, Residual
1
Mandibular Neoplasms
1
Lymphoma, Follicular
1
Lipid Metabolism Disorders
1
Huntington Disease
1
Fatigue
1
Diabetes Mellitus
1
Interventions
Data Collection
3
telitacicept
1
human papillomavirus vaccine, L1 type 16, 18
1
Vitamin D
1
Telemedicine
1
Plasma Exchange
1
Mycophenolic Acid
1
Immune Checkpoint Inhibitors
1
Fish Oils
1
Fatty Acids, Omega-3
1
Eicosapentaenoic Acid
1
Docosahexaenoic Acids
1
Cholecalciferol
1
CT-P13
1
Azathioprine
1
Ashwagandha
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Autoimmune Diseases
×
Docosahexaenoic Acids
×
Clear all
NCT01351805
2025-12-03
VITAL
Brigham and Women's Hospital
Phase NA
Completed
25,871 enrolled
15 charts